Summary of Idorsia's Conference Call Company Overview - **Company**: Idorsia - **Key Products**: - QUVIVIQ: A dual orexin receptor antagonist for insomnia - TRYVIO (also known as JERAYGO): An endothelin receptor antagonist for systemic hypertension - **Pipeline**: Built on the legacy of Actelion, with a focus on drug discovery and development Financial Position - **Debt Restructuring**: Successfully restructured debt situation, leading to an unencumbered equity story for Idorsia [3] - **Sales Performance**: - QUVIVIQ sales in 2025 reached CHF 134 million, outperforming the guidance of CHF 130 million [6] - Outlook for 2026 sales is around CHF 200 million [6] QUVIVIQ Insights - **Geographic Performance**: - Strong growth in Europe and Canada, with a focus on reimbursement strategies [5] - Notable uptake in Japan, where DORA class accounts for 37% of the insomnia market [4] - In China, 300,000-400,000 patients on QUVIVIQ within the first six months of launch [4] - **Market Strategy**: - Focus on neurologists and psychiatrists initially, followed by general practitioners (GPs) for broader adoption [8] - Co-promotion partnerships in Europe to enhance market access [8] U.S. Market Challenges - **Scheduling Issues**: QUVIVIQ is the third DORA approved by the FDA, facing scheduling challenges due to historical precedents [9][10] - **Citizen Petition**: Submitted to the FDA in April 2023 to address scheduling concerns based on global usage data showing no abuse potential [11][12] Pediatric Data - **Pediatric Program**: Phase 2 dose-finding study for pediatric insomnia expected to report results in Q1 or Q2 2024 [14] - **Potential Impact**: Positive outcomes could support descheduling efforts and improve access for children with sleep disorders [16] Lucerastat for Fabry Disease - **Product Overview**: Oral substrate reduction therapy with advantages over enzyme replacement therapies [17] - **Clinical Development**: Pivotal trial design includes a renal function study based on eGFR [18] - **Market Position**: Positioned as a broadly applicable treatment for Fabry disease, with potential expansion into other lysosomal storage diseases [19] TRYVIO (JERAYGO) Updates - **Approval Status**: Approved in the U.S. and Europe for systemic hypertension [27] - **Differentiation**: Unique profile with no signals for hyperkalemia or hyponatremia, applicable to patients inadequately controlled on other therapies [27][28] - **Partnership Strategy**: Seeking partnerships to maximize value, particularly in cardiology and nephrology [30][31] Pipeline Developments - **CCR6 Antagonist**: Initiated proof of concept study in psoriasis, with potential for expansion into other T helper 17 mediated diseases [34][35] - **CXCR7 for Progressive MS**: Trial initiation expected soon, focusing on anti-inflammatory and remyelinating benefits [36] - **CXCR3 for Vitiligo**: Aiming to disrupt melanocyte targeting, with plans to initiate trials later this year [41][42] Conclusion - **Overall Strategy**: Idorsia is focused on leveraging its unique product offerings and pipeline to create value, while navigating financial challenges and market dynamics [44]

Core Insights - Idorsia Ltd reported strong financial and operational results for the full year 2025, setting a foundation for future growth and a catalyst-rich 2026 [1][2] Financial Performance - Net sales for 2025 reached CHF 221 million, a significant increase from CHF 113 million in 2024, driven by product sales of CHF 134 million and contract revenues of CHF 79 million [9] - Operating expenses decreased to CHF 268 million in 2025 from CHF 351 million in 2024, influenced by a one-off gain from a deal amendment [10] - The net loss for 2025 was CHF 112 million, an improvement from a net loss of CHF 264 million in 2024, resulting in a net loss per share of CHF 0.52 compared to CHF 1.45 in the previous year [11][12] Product Highlights - QUVIVIQ sales more than doubled, contributing significantly to the revenue growth and positioning the product for blockbuster status [2][6] - TRYVIO/JERAYGO has been approved in multiple regions and is showing promising results in hypertension treatment, with ongoing discussions for partnerships to maximize its global value [7][10] - The company is advancing its pipeline, including the upcoming pediatric insomnia study for daridorexant and the registration program for lucerastat in Fabry disease [6][8] Strategic Outlook - The guidance for 2026 anticipates continued growth in QUVIVIQ sales, projected to increase by approximately 50%, alongside investments in the lucerastat registration program and the immunology portfolio [8] - The company aims to transform the treatment paradigm in pediatric insomnia, with results expected in Q2 2026 [7] - Idorsia's operational restructuring initiated in Q4 2024 has contributed to improved financial performance and a strengthened balance sheet [11][13] Human Resources - The company reduced its workforce by over 200 positions in 2025, bringing the total number of permanent employees to 487 [20]

Core Insights - Idorsia Ltd has launched a groundbreaking initiative called IMPACT-HTN in collaboration with Stanford Hypertension Center and Duke Heart Center to modernize the management of difficult-to-control hypertension [1][2][4] - The program aims to generate real-world evidence, standardize clinical decision-making, and develop AI-powered tools to improve patient outcomes [1][3][4] - TRYVIO™ (aprocitentan), a new treatment targeting a novel pathway in hypertension, is central to this initiative and has been included in recent clinical practice guidelines [6][16] Company Overview - Idorsia is focused on discovering, developing, and commercializing transformative medicines, with a commitment to improving patient outcomes beyond just medication [4][17] - The company is headquartered in Allschwil, Switzerland, and is listed on the SIX Swiss Exchange under the ticker symbol IDIA [18] Industry Context - Hypertension affects approximately 50% of adults in the US, posing significant health risks including cardiovascular events and premature mortality [2] - The IMPACT-HTN program addresses the challenges faced by patients with difficult-to-control hypertension, who often require multiple medications and face coordination issues [1][2][3] Program Details - The IMPACT-HTN initiative consists of three phases aimed at improving care for patients with difficult-to-control hypertension [1][3] - Key components of the program include a digital care algorithm, a personalized hypertension risk score, and a prospective early patient experience initiative [5]

Core Viewpoint - Idorsia Ltd announces the appointment of Dr. Srishti Gupta as the new CEO effective July 1, 2025, succeeding André C. Muller, who will transition to an advisory role to ensure a smooth leadership change [1][3][4]. Group 1: Leadership Transition - Dr. Srishti Gupta has been a board member since 2021 and is well-positioned to lead the company due to her deep understanding of Idorsia's operations and product portfolio [1][2]. - André C. Muller, the current CEO, will retire and take on an advisory role, having successfully led the company through financial restructuring and the commercial ramp-up of QUVIVIQ in the EUCAN region [3][4]. - The leadership transition aims to maintain stability and continuity as the company focuses on advancing its product portfolio and achieving profitability by the end of 2027 [4][5]. Group 2: Dr. Srishti Gupta's Background - Dr. Gupta has over 20 years of experience in global health and biopharmaceutical innovation, with a strong background in strategy and healthcare systems [2][8]. - She previously spent 18 years at McKinsey & Company, where she held senior leadership roles in the pharmaceutical and global health practices [2][9]. - Dr. Gupta holds an MD from Harvard Medical School and multiple degrees from Harvard University and the University of Cambridge, showcasing her strong academic credentials [8][9]. Group 3: Company Outlook - The company is optimistic about the commercial success of QUVIVIQ, which is gaining traction in Europe, and is reactivating collaboration discussions for TRYVIO [5][12]. - Dr. Gupta emphasizes the need for balancing ambition with financial discipline, indicating a focus on smart investments in promising assets [5][6]. - Idorsia aims to evolve into a leading biopharmaceutical company, committed to discovering and commercializing transformative medicines [11][12].